In seeking to understand whether HUWE1-mediated PARPi resistance occurs in the clinical disease as well as in cell lines, we analysed DNA sequencing from tumor and ctDNA from a 54 year old patient with high grade serous ovarian cancer who received the PARP inhibitor olaparib as part of the ComPAKT Phase Ib trial (in combination with the AKT inhibitor capivasertib [44]). This evidence concerns the gene PARP1 and ovarian serous adenocarcinoma.